In any case, the function of TCF19 in NRAS‐mutant melanoma, especially in BRAF/MAPK inhibitor and immune therapy resistance, is worthy to study further to better understand the mechanisms of how TCF19 is upregulated in NRAS‐mutant melanoma and how it governs the resistance to immune therapy. This evidence concerns the gene NRAS and melanoma.